Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (Credence)

Pridané:
23.5.2019
Autori: 
V. Perkovic, M.J. Jardine, B. Neal, S. Bompoint, H.J.L. Heerspink, D.M. Charytan, R. Edwards, R. Agarwal, G. Bakris, S. Bull, C.P. Cannon, G. Capuano, P.-L. Chu, D. de Zeeuw, T. Greene, A. Levin, C. Pollock, D.C. Wheeler, Y. Yavin, H. Zhang, B. Zinman, G. Meininger, B.M. Brenner, and K.W. Mahaffey, for the CREDENCE Trial Investigators ** This article was published on April 14, 2019, at NEJM.org. DOI: 10.1056/NEJMoa1811744
Zdroj: 
The NEW ENGLAND JOURNAL of MEDICINE